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Roger S. Blumenthal, MD, Chiadi E. Ndumele, MD, MHS, Seth S. Martin, MD
Baltimore, MarylandThe clinical utility of high-sensitivity C-reactive protein
(hsCRP) testing in patients being considered for statin
therapy or already taking statins is an area of intense interest.
Creative avenues of investigation into the vascular biology of
inﬂammation have taken the concept of atherosclerotic pla-
que formation from passive lipid deposition to an interactive
process of lipids networking with the innate and adaptive
immune systems. Amid a rich body of basic, translational,
and clinical science, the idea of bringing inﬂammation to the
bedside in preventing and treating atherosclerotic cardio-
vascular disease (CVD) continues to stir controversy.
In this issue of the Journal, Sever et al. (1) evaluate theSee page 717relationship of baseline and on-treatment hsCRP levels with
cardiovascular events among hypertensive patients in the
ASCOT-LLA (Anglo-Scandinavian Cardiac Outcomes
Trial Lipid-Lowering Arm). As has been demonstrated in
multiple previous prospective studies, baseline hsCRP levels
predicted incident CVD. However, across tertiles of baseline
hsCRP levels, no difference was detected in the relative effect
of statin therapy. After 6 months of atorvastatin 10 mg/day,
median levels of hsCRP dropped by 26% and low-density
lipoprotein cholesterol (LDL-C) by 39%. Although
achieving LDL-C levels below the median at 6 months was
associated with lower CVD risk, a clear risk reduction was not
seen for hsCRP levels below the median.
The current report extends the ﬁndings of an earlier
nested case-control ASCOT study (2) indicating that
baseline and on-treatment hsCRP levels may not mean-
ingfully predict beneﬁt of statins. The newest report incor-
porates increased statistical power with 456 major CVD
events included in baseline analyses and 170 cases in on-
treatment analyses. Similar to the JUPITER (Justiﬁcation
for the Use of Statins in Primary Prevention: An Interven-
tion Trial Evaluating Rosuvastatin) trial, the ASCOT-LLA
takes place in the primary prevention setting, although the*Editorials published in the Journal of the American College of Cardiology reﬂect the
views of the authors and do not necessarily represent the views of JACC or the
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relevant to the contents of this paper to disclose.baseline mean LDL-C was higher (129 mg/dl vs. 104 mg/
dl) and hsCRP was lower (2.4 vs. 4.2 mg/l) in the ASCOT-
LLA versus the JUPITER (3).
Having just taken part in another historical presidential
election in the United States, it seems ﬁtting to reﬂect on the
Inaugural Presidential Address of John F. Kennedy. On
January 20, 1961, he proclaimed, “ask not what your country
can do for youdask what you can do for your country.” In the
same vein, of the ASCOT, might we say, ASK NOT what
CRP can do for youdask what you can do for your CRP?We
can imagine that if President Obama was briefed on this
ASCOT-LLA report and asked to prioritize national
resources for routine serial hsCRP testing in the primary
prevention setting, he might react with his “McKayla Mar-
oney is not impressed” face.
Nevertheless, this report from the ASCOT-LLA is obser-
vational and has other signiﬁcant limitations that must be
considered. Despite the large overall number of events, a more
limited number of cases had on-treatment hsCRP data. As
shown inTable 4, on-treatment hsCRP levels below themedian
were associated with consistent trends toward beneﬁt, with
nonsigniﬁcant risk reductions of 34% for coronary heart disease
(CHD) events and 22% for CVD events in fully adjusted
models.Ashas been suggestedpreviously (4), it remains possible
that with greater statistical power, signiﬁcant reductions in
CVDmight have been observed. This notion is supported by an
analysis using imputed data for missing covariates (Table 5),
which contained additional events and demonstrated that ach-
ieved hsCRP levels less than the median were associated with
a signiﬁcant 39%reduction inCHDevents and a 30% reduction
in CVD events bordering on statistical signiﬁcance (p¼ 0.07).
Post hoc analysis of the JUPITER, better powered for on-
treatment analyses, suggests that lower hsCRP levels may
indicate greater degrees of success with statin treatment (5).
In addition, the ASCOT-LLA population is >80% men,
entirely white, and older in age; given known demographic
variations in hsCRP levels, the results might not be fully
generalizable to women, nonwhite ethnicities, or younger
patients. Furthermore, the results of serial hsCRP assess-
ments in this primary prevention trial may also not be
generalizable to post-ACS or CHD patients, settings where
lower on-treatment hsCRP levels have been associated with
reduced risk.
There is inconsistent evidence regarding the utility of
hsCRP measurements for targeting statin therapy for primary
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731prevention. In the AFCAPS/TexCAPS (Air Force/Texas
Coronary Atherosclerosis Prevention Study), baseline hsCRP
levels differentiated which patients with relatively low
LDL-C levels beneﬁted from statin therapy (6). In contrast,
in the Heart Protection Study of 20,536 at-risk individuals
bridging the primary and secondary prevention spheres,
statin therapy conferred a 29% relative risk reduction even
if baseline hsCRP was <1.25 mg/l (7). In the analysis by
Sever et al. (1) of the ASCOT-LLA, participants showed
similar proportional statin effects across baseline hsCRP
levels. The 2010 American College of Cardiology Founda-
tion/American Heart Association guidelines on Assessment
of Risk in Asymptomatic Adults give a Class IIa indication to
measure hsCRP in persons meeting JUPITER entry criteria
(8). Ultimately, however, the absolute statin beneﬁt depends
on absolute risk, to which hsCRP adds modest incremental
information to clinical metrics already in routine use (9).
Regarding hsCRP testing to guide ongoing statin therapy
in the primary prevention setting, in the absence of a trial
randomizing patients to on-treatment hsCRP monitoring or
not, studies like the current ASCOT-LLA are helpful to
inform clinical practice. In a cost-constrained healthcare
system, it is crucial to appraise these existing data to assess
whether the information gained from sending an hsCRP
level justiﬁes the added cost of w$30 (10).
At the population-level, statin therapy lowered hsCRP
levels by 26% in the ASCOT-LLA and 37% in the
JUPITER (2). Closer to the bedside, at the patient-level,
some studies suggest a heterogeneous response of hsCRP
levels to statins with 30% to 40% of patients seeing no change
or an increase in hsCRP on treatment (11). Moreover,
a lingering fundamental issue is the potential lack of causality
of CRP in CVD suggested by Mendelian randomization
(in contrast to LDL-C) (12). Moreover, a previous meta-
regression analysis found that the degree of risk reduction
conferred by statins is completely compatible with the degree
of LDL-C lowering rather than additional pleiotropic effects
(13). Thus, available data do not provide conclusive evidence
to support widespread use of serial hsCRP testing (14).
The most appropriate question may be to ask what you can
do for your hsCRP because lifestyle improvements are the
cornerstone of prevention, and they consistently lower in-
ﬂammatory biomarkers. Moreover, even if CRP is not a causal
risk factor, it reﬂects underlying inﬂammatory processes that
might be causal and modiﬁable with pharmacotherapy. On
this frontier, exciting work is under way. Two cardiovascular
inﬂammation reduction trials will test the impact of canaki-
numab (monoclonal antibody to interleukin-1b) and low-
dose methotrexate on clinical outcomes. We hope that these
innovative trials yield new therapeutic options for our patients.
In the meantime, we are indebted to the pioneering
scientists who have moved the inﬂammatory hypothesis
forward, and we ﬁnd the current ASCOT-LLA report
valuable in placing serial laboratory quantiﬁcation of systemic
inﬂammation in a clinical context. But like the recent presi-
dential debates, this report will add to the intensely partisanconversations regarding the utility of hsCRP testing in
guiding statin therapy without yielding any deﬁnitive
consensus for practice. Clinicians will ultimately cast their
votes in the form of lab orders (or the lack thereof). In
the meantime, we are optimistic that future patient-oriented
discoveries will help bring the concepts of vascular inﬂam-
mation closer to the bedside and make for a more informed
electorate.
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